Vaxcyte reports Q1 net loss $95M, cash $1.9B; VAX-31/24 enrollment complete

Vaxcyte, Inc.

2024-Q1 EPS reported -$0.85

Cash, equivalents and investments $1.9B at March 31, 2024, up from $1.24B at Dec 31, 2023, including $816.5M net from Feb offering.
Net loss $95.0M vs $60.5M in Q1 2023; R&D expenses rose to $94.6M from $58.1M.
VAX-31 adult Ph1/2 enrollment completed; topline safety/immunogenicity data expected Q3 2024.
VAX-24 infant Ph2 enrollment completed; topline data from primary series expected by end Q1 2025.
Plan to advance either VAX-24 or VAX-31 to adult Ph3 after VAX-31 data; if VAX-24, Ph3 start H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vaxcyte, Inc. reported financial results for the first quarter ended March 31, 2024.

Period: the first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Vaxcyte, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-021665

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.